Boqii Holding Ltd

Boqii Holding Limited operates in the online retail and pet industries in China, serving as a platform for pet products and services. The filing does not disclose specific market size or growth rate data for these industries, nor does it detail structural forces shaping competition beyond noting the company's position within the online retail and pet sectors.

The filing does not name specific primary competitors or provide market share data. Management describes competitive advantages as being derived from relationships with customers, users, KOLs, brand partners, manufacturers, strategic partners, offline pet stores and pet hospitals, but no quantitative market share or relative standing is stated.

Boqii generates revenue through the sale of pet products via its online sales platforms, including Boqii Mall, flagship stores on third-party e-commerce platforms, and a proprietary SaaS system, as well as through an offline network. The company operates under a distribution model or drop shipping model where it acts as a principal in transactions, with GMV calculated as the total value of confirmed orders placed regardless of delivery or returns, based on listed prices without considering discounts. Primary customer segments include individual customers and small and medium pet businesses, with active buyers defined as registered accounts that accepted one or more shipped orders on the online sales platforms during a given period.

The filing describes the company's product and service lines through its online sales platforms, which include Boqii Mall, flagship stores on third-party e-commerce platforms, and a proprietary SaaS system, as well as an offline network. The company also operates a content platform and engages with KOLs. For the years ended March 31, 2024, 2025, and 2026, the amount of revenues generated by the VIEs accounted for approximately 71.2% ¹, 55.3% ², and 33.2% ³ of total net revenues, respectively. As of March 31, 2024, 2025, and 2026, total assets of the VIEs, excluding amounts due from other companies in the Company, equaled approximately 44.8% ⁴, 49.1% ⁵, and 36.1% ⁶ of consolidated total assets, respectively.

The filing does not provide a separate breakdown of revenue or margin contribution by individual product or service line beyond the VIE revenue share and the consolidated figures. The company's business activities include value-added telecommunication services and the import of veterinary drugs, which are conducted through the VIEs due to PRC foreign ownership restrictions.

During the fiscal year ended March 31, 2026, the company completed a 160-for-1 share consolidation approved by shareholders on June 26, 2025 ⁷. The ADS program was removed effective July 11, 2025 ⁸, with each ADS previously representing 150 ⁹ Class A ordinary shares. As of March 31, 2026, there were 4,298,128 ¹⁰ Class A ordinary shares, 81,486 ¹¹ Class B ordinary shares, and 500,000 ¹² Class C ordinary shares issued and outstanding. The company made cumulative capital contributions of approximately RMB1,220.8 million (approximately US$177.0 million) ¹³ to its PRC subsidiaries through intermediate holding companies as of March 31, 2026. No service fees were charged to the VIEs by the WFOEs for the years ended March 31, 2024, 2025, and 2026 ¹⁴.

For the fiscal year ended March 31, 2026, total net revenues were RMB420,467 thousand ¹⁵, compared to RMB468,894 thousand ¹⁶ in the prior year and RMB709,352 thousand ¹⁷ in fiscal 2024. Net loss attributable to Boqii Holding Limited was RMB5,078 thousand ¹⁸ for fiscal 2026, compared to a net loss of RMB54,125 thousand ¹⁹ in fiscal 2025 and a net loss of RMB63,664 thousand ²⁰ in fiscal 2024. Gross profit was RMB110,439 thousand ²¹ in fiscal 2026, compared to RMB100,654 thousand ²² in fiscal 2025 and RMB140,737 thousand ²³ in fiscal 2024. Loss from operations improved to RMB29,966 thousand ²⁴ in fiscal 2026 from RMB59,321 thousand ²⁵ in fiscal 2025 and RMB60,159 thousand ²⁶ in fiscal 2024.

The filing does not discuss specific growth vectors such as new products, new markets, new customer segments, geographic expansion, strategic partnerships, pending acquisitions, or technology investments with stated opportunity sizes or expected revenue contributions.

The filing does not discuss specific growth vectors such as new products, new markets, new customer segments, geographic expansion, strategic partnerships, pending acquisitions, or technology investments with stated opportunity sizes or expected revenue contributions.

The filing does not provide a margin and cost outlook, margin trajectory, cost structure evolution, or efficiency or restructuring targets with exact figures.

The filing does not provide an operational outlook regarding supply chain posture, manufacturing capacity, technology infrastructure investments, or headcount and workforce strategy.

The filing does not disclose R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy with exact figures. The company states it has not previously declared or paid any cash dividend and has no plan to declare or pay any dividends in the near future.

The filing does not discuss structural headwinds or execution risks explicitly flagged by management to the growth plan.

The filing does not discuss geographic, regulatory, or macro factors management identified as constraints.

The most material and specific risks to Boqii's business arise from its reliance on variable interest entity (VIE) contractual arrangements to conduct operations in China, as the company is a Cayman Islands holding company with no business operations of its own. For the years ended March 31, 2024, 2025, and 2026, revenues generated by the VIEs accounted for approximately 71.2% , 55.3% , and 33.2% of total net revenues, respectively, and as of March 31, 2026, total assets of the VIEs equaled approximately 36.1% of consolidated total assets. If the PRC government determines these contractual arrangements violate restrictions on foreign investment in value-added telecommunication services or veterinary drug importation, the company could be subject to material penalties or forced to relinquish its interests, potentially rendering the Class A ordinary shares worthless. Additionally, the company faces significant uncertainty regarding future PRC government actions that could affect the legality and enforceability of these VIE agreements, which have not been tested in a PRC court. The company's ability to pay dividends is constrained by PRC laws requiring subsidiaries to set aside at least 10% ²⁷ of after-tax profits each year to statutory reserve funds until the aggregate amount reaches 50% ²⁸ of registered capital, and by restrictions on foreign exchange and the conversion of Renminbi into foreign currencies for capital expenses.

The overall tone of management's message, as reflected in the filing, is cautious and focused on the structural and regulatory risks inherent in the company's VIE structure and operations in China. Management emphasizes the uncertainty surrounding the legality and enforceability of the contractual arrangements with the VIEs, noting that if the PRC government deems these arrangements non-compliant, the company could be subject to material penalties or forced to relinquish its interests.